Cargando…

Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer

The epidermal growth factor receptor 2 (HER-2) oncogene is a major target for the immunotherapy of breast cancer. Following up to the therapeutic success achieved with Her-2-targeting monoclonal antibodies, immune-prophylactic approaches directed against Her-2 have also been investigated taking into...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacca, Sarah, Rolih, Valeria, Quaglino, Elena, Franceschi, Valentina, Tebaldi, Giulia, Bolli, Elisabetta, Rosamilia, Alfonso, Ottonello, Simone, Cavallo, Federica, Donofrio, Gaetano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839386/ https://www.ncbi.nlm.nih.gov/pubmed/27141335 http://dx.doi.org/10.1080/2162402X.2015.1082705

Ejemplares similares

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

DNA vaccination against oncoantigens: A promise
por: Iezzi, Manuela, et al.
Publicado: (2012)

BoHV-4-based vector delivering Ebola virus surface glycoprotein
por: Rosamilia, Alfonso, et al.
Publicado: (2016)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

BoHV-4 immediate early 1 gene is a dispensable gene and its product is not a bone marrow stromal cell antigen 2 counteracting factor
por: Franceschi, Valentina, et al.
Publicado: (2015)

Multi-level model for the investigation of oncoantigen-driven vaccination effect
por: Cordero, Francesca, et al.
Publicado: (2013)

Induction of Antihuman C–C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector
por: Verna, Andrea Elizabeth, et al.
Publicado: (2017)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice
por: Conti, Laura, et al.
Publicado: (2014)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

Bovine Herpesvirus-4-Based Vector Delivering Peste des Petits Ruminants Virus Hemagglutinin ORF Induces both Neutralizing Antibodies and Cytotoxic T Cell Responses
por: Macchi, Francesca, et al.
Publicado: (2018)

Accelerated Mammary Tumor Onset in a HER2/Neu Mouse Model Exposed to DDT Metabolites Locally Delivered to the Mammary Gland
por: Johnson, Nakpangi A, et al.
Publicado: (2012)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas
por: Muscatello, L. V., et al.
Publicado: (2022)

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
por: Marchini, Cristina, et al.
Publicado: (2013)

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
por: Liu, Zhe, et al.
Publicado: (2012)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
por: Wang, Junbiao, et al.
Publicado: (2022)

Fetal exposure to oncoantigen elicited antigen-specific adaptive immunity against tumorigenesis
por: Chen, Jeng-Chang, et al.
Publicado: (2020)

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
por: Chong, Qing-Yun, et al.
Publicado: (2017)

Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis
por: Fry, Elizabeth A., et al.
Publicado: (2013)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Immunization With Bovine Herpesvirus-4-Based Vector Delivering PPRV-H Protein Protects Sheep From PPRV Challenge
por: Rodríguez-Martín, Daniel, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q8hqls6thppi5lukg28ipj1faa